Home > Insider Trading > Filing (0001439222-24-000063)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc.	AGIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1405288	A Jacqualyn Fouse	C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-04-08	15,934	$0.00	145,187	No	4	M	Direct
Common Stock	Disposition	2024-04-10	7,791	$27.55	137,396	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted stock units	Disposition	2024-04-08	15,934	$0.00	15,934	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,933			No	4	M	Direct

Footnotes

Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated April 8, 2022.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.